Zura Bio (ZURA) AI Stock Analysis

• Market Cap: $342.02M
• Dividend Yield: N/A
• Average Volume (3M): 2.99M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.38
• Revenue Growth: N/A
• EPS Growth: -19.69%
• Country: US
• Employees: 30
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.21
• Shares Outstanding: 65,023,310
• 10 Day Avg. Volume: 1,304,161
• 30 Day Avg. Volume: 2,987,270
• PEG Ratio: 0.06
• Price to Book (P/B): 1.28
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -6.67
• Enterprise Value/Market Cap: -0.12
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 1.69K
• Enterprise Value/Ebitda: 0.61
• 1Y Price Target: $16.50
• Price Target Upside: 254.84% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 56 Neutral
• Price Target: $5.00 ▲(7.53% Upside)

The score is held back primarily by weak financial performance (pre-revenue, widening losses, and significant cash burn), partially offset by strong technical momentum (price above key moving averages with positive MACD). Corporate events are a modest positive due to the cleanup/reset of agreements and related risk reduction, while valuation is difficult to assess given the negative P/E and no dividend yield data.

Positive Factors

Focused Immunology Pipeline

A concentrated pipeline targeting IL-17 and interferon-gamma shows a clear therapeutic focus in autoimmune/inflammatory disease. This specialization supports durable R&D expertise, potential for differentiated clinical data, and makes the company a more attractive partner or acquisition target over the medium term.

Low Financial Leverage

Zero reported debt and positive shareholders' equity provide financial flexibility to fund clinical programs without immediate interest burden. Lower leverage reduces insolvency risk and preserves optionality for strategic moves, giving management time to advance assets before relying on high-cost funding.

Corporate Agreement Reset

Termination and replacement of prior arrangements plus broad releases reduce legacy legal overhang and counterparty risk. Combined with planned internal-control enhancements, this structural cleanup should improve governance clarity and allow management to focus resources on clinical development and partner engagements.

Negative Factors

Pre-revenue with Widening Losses

Being pre-revenue with materially negative net income reflects a structural lack of operating cash inflows and no margin base. Continued negative earnings mean long-term viability depends on successful clinical outcomes or external funding, increasing execution and dilution risk over the next several quarters.

High and Rising Cash Burn

Sizable negative operating and free cash flow that worsened year-over-year signals ongoing high cash consumption to fund trials. Reliance on external financing is structural; recurring cash burn can compress runway, force funding rounds, and delay programs if capital markets or partner deals are unavailable.

Leadership and Governance Turnover

A CEO medical leave with an interim carrying multiple roles, plus recent board departures, creates sustained governance and execution risk. Over months this can slow strategic decisions, complicate partner negotiations and fundraising, and reduce continuity critical for advancing late-stage clinical objectives.

Zura Bio Business Overview & Revenue Model

Company Description

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.

How the Company Makes Money

Zura Bio generates revenue through the development and commercialization of its proprietary drug candidates. The company's primary revenue streams include licensing agreements, partnerships with other pharmaceutical companies, and potential sales of successfully developed therapies. Zura Bio collaborates with strategic partners for clinical development, regulatory approval, and distribution of its products, which can result in milestone payments and royalties. Additionally, the company may engage in research and development collaborations that provide funding and resource sharing to advance its product pipeline.

Zura Bio Financial Statement Overview

Summary

Zura Bio is facing financial difficulties with no revenue generation and increasing losses. The strong cash position and absence of debt are positives, providing financial stability in the short term. However, the company must address its operational inefficiencies and explore revenue generation strategies to ensure long-term viability. The current trajectory is unsustainable without a shift in operational or strategic direction.

Income Statement

Zura Bio has consistently reported zero revenue over the past three years, with increasing net losses. This reflects a challenging financial position in terms of generating income. The negative EBIT and EBITDA margins further highlight inefficiencies in cost management or lack of operational revenues.

Balance Sheet

The balance sheet shows a strong cash position with no debt, which provides a buffer against operational losses. The company's equity has significantly improved over the years, moving from negative to positive, indicating some financial recovery. However, the lack of revenue generation is a concern despite the strong cash reserves.

Cash Flow

Operating cash flow remains negative, reflecting ongoing operational challenges. The free cash flow is also negative, indicating that the company is not generating enough cash to cover its capital expenditures. While financing cash flow is positive, suggesting successful fundraising efforts, reliance on external financing could be risky without revenue improvement.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-25.00K	0.00	0.00	0.00	0.00
EBITDA	-68.94M	-55.18M	-62.64M	-27.16M	8.42M
Net Income	-62.52M	-52.40M	-60.36M	-25.74M	8.42M
Balance Sheet
Total Assets	143.94M	179.53M	100.84M	5.26M	140.55M
Cash, Cash Equivalents and Short-Term Investments	139.02M	176.50M	99.81M	1.57M	729.22K
Total Debt	0.00	0.00	0.00	7.76M	0.00
Total Liabilities	25.49M	19.51M	21.29M	27.32M	10.35M
Stockholders Equity	108.24M	146.81M	59.33M	-32.06M	130.20M
Cash Flow
Free Cash Flow	-53.50M	-28.15M	-23.05M	-13.20M	-1.10M
Operating Cash Flow	-53.36M	-28.08M	-15.05M	-1.20M	-1.10M
Investing Cash Flow	-141.00K	-5.08M	-8.00M	-12.00M	-139.38M
Financing Cash Flow	4.29M	109.84M	121.29M	14.77M	141.21M

Zura Bio Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.65
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ZURA, the sentiment is Positive. The current price of 4.65 is above the 20-day moving average (MA) of 4.61, above the 50-day MA of 4.13, and above the 200-day MA of 2.37, indicating a bullish trend. The MACD of 0.35 indicates Negative momentum. The RSI at 64.18 is Neutral, neither overbought nor oversold. The STOCH value of 59.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ZURA.

Zura Bio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PBYI	76 Outperform	$312.42M	8.37	39.69%	―	-12.96%	56.02%
VTYX	63 Neutral	$987.60M	-9.23	-45.35%	―	―	36.65%
ZURA	56 Neutral	$342.02M	-7.43	-47.85%	―	―	-19.69%
CLLS	54 Neutral	$324.81M	-13.44	-31.07%	―	158.54%	66.90%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VOR	47 Neutral	$280.02M	-0.03	―	―	―	-1072.48%
PRQR	42 Neutral	$220.95M	-4.60	-99.45%	―	-11.99%	-42.04%

Zura Bio Corporate Events

Zura Bio resets key agreements after internal review

On December 29, 2025, Zura Bio Limited entered into a new Letter Agreement with Athanor Capital and, on the same date, executed settlement and release agreements with Stone Peach and BAFFX17, terminating all outstanding agreements with those parties and securing broad releases of claims in favor of Zura Bio, its subsidiaries and affiliates. Following an internal review conducted by an independent Audit Subcommittee, which was formed and reported on in 2025, the board determined that replacing the Stone Peach arrangements with the Athanor Agreement was more commercially advantageous for the company and its shareholders, and that voiding or terminating the Stone Peach and BAFFX17 agreements would cleanly reset those relationships without financial restatements or findings of employee misconduct; the company now plans incremental enhancements to its internal controls and disclosure procedures that are not expected to materially alter its existing control framework.

The most recent analyst rating on (ZURA) stock is a Hold with a $5.50 price target. To see the full list of analyst forecasts on Zura Bio stock, see the ZURA Stock Forecast page.

Zura Bio Director Resignation Sparks Governance Adjustments

On December 11, 2025, Arnout Ploos van Amstel resigned from Zura Bio Limited’s Board of Directors, effective immediately. His departure also includes resignation from the Nominating and Governance Committee of the Board and was not due to any disagreement regarding the company’s operations, policies, or practices. This change is likely to prompt adjustments in the company’s governance structure, given the loss of contribution from a key board member.

The most recent analyst rating on (ZURA) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Zura Bio stock, see the ZURA Stock Forecast page.

Zura Bio CEO Takes Medical Leave, Interim Appointed

On October 8, 2025, Zura Bio Limited announced that its CEO, Robert Lisicki, will take a medical leave of absence starting October 10, 2025. In his absence, Kim Davis, the company’s Chief Operating Officer, Chief Legal Officer, and Corporate Secretary, has been appointed as the interim CEO and principal executive officer, while continuing her current roles.

The most recent analyst rating on (ZURA) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Zura Bio stock, see the ZURA Stock Forecast page.